IRIS Accounts Production v26.2.5.4 14747173 Board of Directors 1.4.25 31.3.26 31.3.26 false true false false true false Ordinary 1.00000 Ordinary A 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh147471732025-03-31147471732026-03-31147471732025-04-012026-03-31147471732024-03-31147471732024-04-012025-03-31147471732025-03-3114747173ns15:EnglandWales2025-04-012026-03-3114747173ns14:PoundSterling2025-04-012026-03-3114747173ns10:Director12025-04-012026-03-3114747173ns10:PrivateLimitedCompanyLtd2025-04-012026-03-3114747173ns10:SmallEntities2025-04-012026-03-3114747173ns10:AuditExempt-NoAccountantsReport2025-04-012026-03-3114747173ns10:SmallCompaniesRegimeForDirectorsReport2025-04-012026-03-3114747173ns10:SmallCompaniesRegimeForAccounts2025-04-012026-03-3114747173ns10:FullAccounts2025-04-012026-03-3114747173ns10:OrdinaryShareClass12025-04-012026-03-3114747173ns10:OrdinaryShareClass22025-04-012026-03-3114747173ns5:CurrentFinancialInstruments2026-03-3114747173ns5:CurrentFinancialInstruments2025-03-3114747173ns5:Non-currentFinancialInstruments2026-03-3114747173ns5:Non-currentFinancialInstruments2025-03-3114747173ns5:ShareCapital2026-03-3114747173ns5:ShareCapital2025-03-3114747173ns5:RetainedEarningsAccumulatedLosses2026-03-3114747173ns5:RetainedEarningsAccumulatedLosses2025-03-3114747173ns10:RegisteredOffice2025-04-012026-03-3114747173ns5:OwnedOrFreeholdAssetsns5:LandBuildings2025-04-012026-03-3114747173ns5:LeaseholdImprovements2025-04-012026-03-3114747173ns5:ComputerEquipment2025-04-012026-03-3114747173ns5:LandBuildings2025-03-3114747173ns5:LeaseholdImprovements2025-03-3114747173ns5:ComputerEquipment2025-03-3114747173ns5:LandBuildings2025-04-012026-03-3114747173ns5:LandBuildings2026-03-3114747173ns5:LeaseholdImprovements2026-03-3114747173ns5:ComputerEquipment2026-03-3114747173ns5:LandBuildings2025-03-3114747173ns5:LeaseholdImprovements2025-03-3114747173ns5:ComputerEquipment2025-03-3114747173ns5:WithinOneYearns5:CurrentFinancialInstruments2026-03-3114747173ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3114747173ns5:CurrentFinancialInstruments2025-04-012026-03-3114747173ns5:Non-currentFinancialInstruments2025-04-012026-03-3114747173ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2026-03-3114747173ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2025-03-3114747173ns10:OrdinaryShareClass12026-03-3114747173ns10:OrdinaryShareClass22026-03-31
REGISTERED NUMBER: 14747173 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 March 2026

for

JONES & HARRIES PHARM LIMITED

JONES & HARRIES PHARM LIMITED (REGISTERED NUMBER: 14747173)

Contents of the Financial Statements
for the Year Ended 31 March 2026










Page

Balance Sheet 1

Notes to the Financial Statements 3


JONES & HARRIES PHARM LIMITED (REGISTERED NUMBER: 14747173)

Balance Sheet
31 March 2026

2026 2025
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 1,053,139 982,923

CURRENT ASSETS
Stocks 5 65,603 43,000
Debtors 6 337,546 272,275
Cash at bank 10,446 579
413,595 315,854
CREDITORS
Amounts falling due within one year 7 493,072 434,400
NET CURRENT LIABILITIES (79,477 ) (118,546 )
TOTAL ASSETS LESS CURRENT LIABILITIES 973,662 864,377

CREDITORS
Amounts falling due after more than one
year

8

(982,599

)

(840,297

)

PROVISIONS FOR LIABILITIES (2,356 ) (2,929 )
NET (LIABILITIES)/ASSETS (11,293 ) 21,151

CAPITAL AND RESERVES
Called up share capital 10 100 100
Retained earnings (11,393 ) 21,051
SHAREHOLDERS' FUNDS (11,293 ) 21,151

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2026.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2026 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

JONES & HARRIES PHARM LIMITED (REGISTERED NUMBER: 14747173)

Balance Sheet - continued
31 March 2026


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 15 July 2026 and were signed on its behalf by:





Mr T E Harries - Director


JONES & HARRIES PHARM LIMITED (REGISTERED NUMBER: 14747173)

Notes to the Financial Statements
for the Year Ended 31 March 2026


1. STATUTORY INFORMATION

Jones & Harries Pharm Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 14747173

Registered office: Wellness Pharmacy
Newport Road
Old St. Mellons
Cardiff
CF3 5UN

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Freehold property - No depreciation charged
Improvements to property - 5% Straight line
Office equipment - 25% Straight line

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


JONES & HARRIES PHARM LIMITED (REGISTERED NUMBER: 14747173)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 10 (2025 - 7 ) .

4. TANGIBLE FIXED ASSETS
Improvements
Freehold to Office
property property equipment Totals
£    £    £    £   
COST
At 1 April 2025 967,170 - 19,803 986,973
Additions - 74,015 2,269 76,284
At 31 March 2026 967,170 74,015 22,072 1,063,257
DEPRECIATION
At 1 April 2025 - - 4,050 4,050
Charge for year - 864 5,204 6,068
At 31 March 2026 - 864 9,254 10,118
NET BOOK VALUE
At 31 March 2026 967,170 73,151 12,818 1,053,139
At 31 March 2025 967,170 - 15,753 982,923

5. STOCKS
2026 2025
£    £   
Stocks 65,603 43,000

JONES & HARRIES PHARM LIMITED (REGISTERED NUMBER: 14747173)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026


6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Trade debtors 265,816 133,276
Other debtors 67,850 32,721
Prepayments and accrued income 3,880 106,278
337,546 272,275

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2026 2025
£    £   
Bank loans and overdrafts (see note 9) 77,864 97,636
Trade creditors 220,435 143,652
Social security and other taxes 8,193 12,815
Other creditors 143,443 180,035
Accruals and deferred income 43,137 262
493,072 434,400

The bank loans are secured by fixed and floating charges over the assets of the company.

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
2026 2025
£    £   
Bank loans (see note 9) 974,880 840,297
Other creditors 7,719 -
982,599 840,297

The bank loans are secured by fixed and floating charges over the assets of the company.

9. LOANS

An analysis of the maturity of loans is given below:

2026 2025
£    £   
Amounts falling due within one year or on demand:
Bank loans 77,864 97,636

Amounts falling due between two and five years:
Bank loans - 2-5 years 974,880 203,217
Bank loans more than 5 years - 637,080
974,880 840,297

JONES & HARRIES PHARM LIMITED (REGISTERED NUMBER: 14747173)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2026


10. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2026 2025
value: £    £   
50 Ordinary 1 50 50
50 Ordinary A 1 50 50
100 100